2nd Quarter - Report — BIOCOM for BIOCOM (2017)

Firm

BIOCOM

Client

BIOCOM

Income

—

Expenses

$100,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocated for a clean re-authorization of FDA user fee agreements. Organized a DC fly-in to discuss oncology issues Co-hosted a congressional briefing on drug cost and value Co-hosted a life science reception

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

Advocated for increased funding for NIH and FDA. Co-hosted a congressional briefing on NIH and FDA funding

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Economics/Economic Development ECN

Discussed Biocom 2017 economic impact report and statewide expansion

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.